Association for Molecular Pathology v. Myriad Genetics, Inc., 569 U.S. 576 (2013), was a Supreme Court case, which decided that "a naturally occurring... 47 KB (5,601 words) - 06:05, 15 December 2023 |
Pathology v. Myriad Genetics lawsuit mentioned below. The patents expire, starting in 2014. Association for Molecular Pathology v. Myriad Genetics was a 2013... 26 KB (2,977 words) - 20:32, 23 January 2024 |
BRCA mutation (section Genetics) patents owned or controlled by Myriad Genetics. Myriad's business model of exclusively offering the diagnostic test led to Myriad growing from being a startup... 71 KB (8,894 words) - 16:26, 9 April 2024 |
Pathology v. Myriad Genetics lawsuit. The patents begin to expire in 2014. Peter Meldrum, CEO of Myriad Genetics, has acknowledged that Myriad has "other... 72 KB (7,828 words) - 14:11, 16 April 2024 |
US Supreme Court decision in Association for Molecular Pathology v. Myriad Genetics, Inc. As a compromise, the Court declared, that exons-only cDNA is... 19 KB (2,275 words) - 19:34, 18 February 2024 |
for genomics and proteomics predictive cancer test products made by Myriad Genetics, Inc. In May 2002, Labcorp announced the acquisition of all outstanding... 41 KB (4,105 words) - 03:56, 25 March 2024 |
John Nicholas ruled in the Federal Court of Australia in favour of a Myriad Genetics patent on the BRCA1 gene. This was a landmark ruling, affirming the... 26 KB (2,978 words) - 13:34, 5 February 2024 |